The high cost of specialty medications requires an array of management techniques, according to a recent presentation at the Academy of Managed Care Pharmacy Nexus 2015. Read more.
Unlike past years, when utilization management and generic utilization drove cost savings, specialty medications require an array of management techniques-both on the pharmacy benefit and the medical benefit, according to a recent presentation at the Academy of Managed Care Pharmacy Nexus 2015.
“These include high-touch member interactions, education, clinical optimization, channel management, and traditional techniques like pre-authorization,” says Alex Dong, PharmD of OmedaRx.
OmedaRx issues a pipeline watch report to help employers understand new medications in development and existing medications that are moving to generic availability.
Related:Top ways to tap value from specialty drugs for chronic care
“[Care management techniques] also include new methods such as site of care optimization, a program being pioneered by only a few health plans and PBMs in the country, one of which is OmedaRx,” Dong says.
Over the next five years, specialty drug spend will grow to account for 50% of total drug spend. No other component of healthcare spending is projected to grow as quickly as specialty medication cost, according to a report by Artemetrix.
“In addition, specialty medications are delivered to patients in an array of settings, which include specialty pharmacies, home infusion, alternate treatment facilities and physicians’ offices,” he says. “Patient experience and cost vary among each setting. Because some of these drugs may improve patient outcomes but some may come with safety concerns, it is imperative that health plans have a trusted source to perform evidence-based-medicine [EBM] reviews for each drug and provide guidance on their formulary.”
According to Dong, most healthcare executives are aware of blockbuster treatments for hepatitis C (Olysio, Sovaldi, Harvoni, and Viekira Pak).
“However, the pipeline is full of similar blockbuster drugs, which many executives might not be fully aware of yet,” he says. “New treatments for cholesterol, cancer, muscular dystrophy, cystic fibrosis, and other complex diseases are set for approval in the next 6 to 12 months and will account for significant increases in specialty spending.”
NEXT: Five recommendations for containing specialty drug spend
Dong has five specific recommendations for containing the specialty drug spend:
Regardless of management strategy, the future holds dramatic increases in cost, but the cost will not be spread across large populations-it will be concentrated among the small number of patients with complex, rare diseases, according to Dong.
Related: Explosion of specialty drugs challenges U.S. healthcare market
“Americans can expect dramatic increases in healthcare costs as a result of these trends. We should focus on evidence-based strategies to ensure these specialized medications are only used when they are likely to deliver optimal health outcomes to patients. There is hope that biosimilars may provide some relief in specialty medication spend.”
However, it will take a while to sort out clinical interchangeability and market dynamics, he says. “We may see more creative contracting with manufacturers that are value based as opposed to volume based.”
How the Contact Center Can Be a Driver of VBC Success
December 23rd 2024Historically, healthcare organizations have considered the contact center to be a cost center, a communications platform for conveying information to patients and plan members. Today, however, AI-enabled contact centers can be drivers of value, especially in a value-based care environment.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen